ABSTRACT Background Calretinin and Wilmśtumour gene (WT1) are mesothelial markers used to confirm the diagnosis of malignant pleural mesothelioma (MPM). Recently, calretinin score assessed by immunohistochemistry (IHC) was implicated with poor prognosis in MPM. We investigated the prognostic value of calretinin and WT1 expression in predicting survival in a series of patients (p) diagnosed of MPM in our institution Methods Fifty two patients diagnosed of MPM in Vall dHebron University Hospital were retrospectively reviewed. Potential prognostic factors analyzed were age, performance status (PS), neutrophil to lymphocyte ratio (NLR), clinical stage, histology, calretinin and WT1 expression. Survival data were calculated by Kaplan-Meier. Results Patient's characteristics: median age 68 years (31-88 years), males 75.5%, PS 1: 67.3%, asbestos exposure 53.1%, clinical stage III: 55.1%, epithelial subtype 71.4% and NLR > 5 in 44.9% of all patients. Calretinin and WT1 IHC expression were available in 47 p and 32 p, and were positive in 41 p (83.7%) and 25 p (78.1%) respectively. All patients were considered initially unresectable and 71.4% received CT. We found a significant association of calretinin and WT1 expression with epithelial histology (p= 0.030 and p = 0.010). The median survival (OS) was 15.2 months. We found a significant increase in OS in patients with epithelial subtype (23.4 vs 5.0 months in epithelial vs no-epithelial, p Conclusion In our series of 52 MPM patients, epithelial histology, PS, NLR and WT1 expression are significant prognostic factors for survival. The prognostic role of WT1 is worth of prospective validation in future studies on MPM. Disclosure All authors have declared no conflicts of interest.
Read full abstract